Acta Endoscopica

, Volume 37, Issue 3, pp 271–283

L’infliximab dans le traitement prolongé de la maladie de Crohn non fistulisante

  • Séverine Vermeire
  • G. Van Assche
  • P. Rutgeerts
Article
  • 61 Downloads

Résumé

L’Infliximab, un anticorps chimérique monoclonal IgG1 dirigé contre le TNF constitue le premier traitement biologique approuvé dans la maladie de Crohn (MC) et s’est avéré efficace dans le traitement de la MC luminale réfractaire ou intolérante au traitement standard par les glucocorticostéroïdes et/ou les immunodépresseurs. La stratégie optimale est l’induction thérapeutique par 5 mg/kg i.v. aux semaines 0-2-6, suivie d’un traitement systématique d’entretien toutes les 8 semaines. L’infliximab produit une cicatrisation rapide des lésions endoscopiques et histologiques. Le traitement d’entretien par infliximab procure une réduction du nombre de complications, d’hospitalisations, et d’interventions chirurgicales associées à la MC. La réponse à l’infliximab peut être renforcée par l’administration concomitante d’un traitement immunosuppresseur. Les problèmes de sécurité concernent principalement l’immunogénicité due à la formation d’anticorps anti-infliximab (ATI) qui peuvent conduire à des réactions perfusionnelles, à la perte de réponse et à des réactions sérologiques retardées induites par les perfusions. Les mesures destinées à réduire cette immunogénicité comportent au cours du traitement d’entretien, l’administration concomitante d’immunomodulateurs et en phase préthérapeutique, l’utilisation de corticoïdes. Une tuberculose latente doit être dépistée avant le début du traitement. D’autres affections opportunistes connaissent un taux légèrement supérieur, principalement chez les patients traités en même temps par immunomodulateurs. Les complications malignes chez les patients traités par anti-TNF ne sont pas accrues.

Mots-clés

infliximab maladie de Crohn 

Long term treatment with infliximab in non-fistulising crohn’s disease

Summary

Infliximab, a chimeric monoclonal IgGl antibody to TNF is the first biological therapy approved for Crohn’s disease and is efficacious in patients with luminal Crohn’s disease refractory or intolerant to standard treatment with glucocorticosteroids and/or immunomodulators. The optimal strategy is induction therapy with infliximab 5 mg/kg IV at weeks 0-2-6 followed by systematic maintenance treatment every 8 weeks. Infliximab induces rapid endoscopic and histologic healing. Long-term maintenance therapy with infliximab results in a reduction of the rate of complications, hospitalisations and surgeries associated with Crohn’s disease. The response to infliximab may be optimized by concomitant immunosuppressive therapy. Safety problems mainly concern immunogenicity due to the formation of antibodies to infliximab (ATI) which may lead to infusion reactions, loss of response and serum sickness-like delayed infusion reactions. Actions to reduce immunogenicity include systematic maintenance therapy, concomitant use of immunomodulators and pre-treatment with corticosteroids. Latent tuberculosis needs to be screened for before onset of therapy. The rate of other opportunistic infections is slightly increased mainly in patients treated concomitantly with immunomodulators. Malignancy rates in patients treated with anti-TNF strategies are not increased.

Key-words

Crohn’s disease infliximab 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994; 35: 360–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255–60.PubMedCrossRefGoogle Scholar
  3. 3.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7.PubMedGoogle Scholar
  4. 4.
    Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37(5): 674–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215–19.PubMedCrossRefGoogle Scholar
  6. 6.
    Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. Comment in: N Engl J Med 1995; 332: 330–1.Google Scholar
  7. 7.
    Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000; 342: 1627–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumour necrosis factor-alpha IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993; 94: 174–81.PubMedGoogle Scholar
  9. 9.
    Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993; 46: 757–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Breese E, Michie C, Nicholls S, Murch S, Williams C, Domizio P, Walker-Smith J, MacDonald T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455–66.PubMedGoogle Scholar
  11. 11.
    Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther. 200;15: 463–473.Google Scholar
  12. 12.
    Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145–57.PubMedCrossRefGoogle Scholar
  13. 13.
    ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002; 50: 206–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 2003; 124: 1774–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115: 250–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Shen C, Van Assche G, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005; 129: 807–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7: 251–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–69.PubMedCrossRefGoogle Scholar
  21. 21.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999; 116: 22–8.PubMedCrossRefGoogle Scholar
  23. 23.
    D’haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 1999; 116: 1029–34.PubMedCrossRefGoogle Scholar
  24. 24.
    Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 402–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006; 63: 433–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D’Haens G, Malaise M, Belaiche J. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818–24.PubMedCrossRefGoogle Scholar
  27. 27.
    Lichtenstein GR, Stein R, Lewis JD, Deren J. Response to infliximab is decreased in the presence of intestinal strictures in patients with Crohn’s disease. Am J Gastroenterol 1999; 94: A2691.Google Scholar
  28. 28.
    Laharie D, Salzmann M, Boubekeur H, Richy F, Amouretti M, Quinton A, Couzigou P, Lamouliatte H, Zerbib F. Predictors of response to infliximab in luminal Crohn’s disease. Gastroenterol Clin Biol 2005; 29: 145–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D’Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn’s Disease. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease. Am J Gastroenterol 2002; 97: 2357–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 2002; 123: 707–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther 2003; 17: 1451–57.PubMedCrossRefGoogle Scholar
  32. 32.
    Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn’s disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001; 31: 146–50.PubMedCrossRefGoogle Scholar
  33. 33.
    Kugathasan S. Prolonged duration of response to infliximab in early pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 2001; 33: S40–43.PubMedGoogle Scholar
  34. 34.
    Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 2003; 98: 833–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Lamireau T, Cezard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies JL, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J; French-Speaking Group for Pediatric Gastroenterology Nutrition. Efficacy and tolerance of infliximab in children and adolescents with Crohn’s disease. Inflamm Bowel Dis 2004; 10: 745–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Vermeire S, Louis E, Rutgeerts P et al. Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. NOD2/CARD15 does not influence response to infliximab in Crohn’s disease. Gastroenterology 2002; 123: 106–11.PubMedCrossRefGoogle Scholar
  37. 37.
    Mascheretti S, Hampe J, Croucher PJ et al. Response to infliximab treatment in Crohn’s disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002; 12: 509–15.PubMedCrossRefGoogle Scholar
  38. 38.
    Mascheretti S, Hampe J, Kuhbacher T et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn’s disease treated with infliximab. Pharmacogenomics J 2002; 2: 127–36.PubMedCrossRefGoogle Scholar
  39. 39.
    Pierik M, Vermeire S, Van Steen K et al. TNF-alpha receptor 1 and 2 (TNFR1 and TNFR2) polymorphisms in IBD and their association with response to infliximab. Aliment Pharmacol & Ther, 2004.Google Scholar
  40. 40.
    Hlavaty T, Pierik M, Henckaerts L et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharmacol Ther 2005; 22: 613–26.PubMedCrossRefGoogle Scholar
  41. 41.
    Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Louis E, El Ghoul Z, Vermeire S et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol & Ther 2004; 19: 511–9.CrossRefGoogle Scholar
  44. 44.
    Louise E, Watier H, Schreiber S, Hampe J, Taillard T, Olson A, Thorne N, Zhang H, Colombel J-F. Polymorphism in IgG receptor gene FCGR3A and response to infliximab in Crohn’s disease: a subanalysis of the ACCENT 1 study. Pharmacogenetics & Genomics, in press.Google Scholar
  45. 45.
    Lemann M, Colombel J, Duclos B, Veyrac M, Dupas J, Delchier J, Laharie D, Moreau J, Cadiot G, Sobhani I, Metman E, Bourreille A. Infliximab in steroid dependent Crohn’s disease patients treated with azathioprine or 6-MP a randomized double-blind placebo-controlled trial. Gut 2003; 52: A44, suppl.Google Scholar
  46. 46.
    Hommes D, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Rutgeerts P, Donner A, Feagan B, D’Haens G. A randomized controlled trial evaluating the ideal medical management for Crohn’s disease (CD): top-down versus step-up strategies. Gastroenterology 2005; 128: A-577.Google Scholar
  47. 47.
    Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importane of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2: 542–553.PubMedCrossRefGoogle Scholar
  48. 48.
    Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Noman M, Vermeire S, Van Assche G, Baert F, D’Haens G, Marceletti J, Do J, Smith KM, Rutgeerts P. The effectiveness of immunosuppression to suppress the formation of antibodies to infliximab in Crohn’s disease. Gastroenterology 2004; 126: A-54–55.Google Scholar
  50. 50.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003; 124: 917–924.PubMedCrossRefGoogle Scholar
  51. 51.
    Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 2003; 125: 32–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275–85.PubMedCrossRefGoogle Scholar
  53. 53.
    Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19–31.PubMedCrossRefGoogle Scholar
  54. 54.
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621–30.PubMedCrossRefGoogle Scholar
  55. 55.
    Marchal L, D’Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D’Hoore A, Penninckx F, Rutgeerts P. The risk of post-operative complications associated with infliximab theapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19: 749–54.PubMedCrossRefGoogle Scholar
  56. 56.
    Colombel JF, Loftus EV Jr. Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99: 878–83.PubMedCrossRefGoogle Scholar
  57. 57.
    Van Assche G, Paintaud G, D’Haens G, Baert F, Vermeire S, Noman M, Watier H, Magdelaine C and Rutgeerts P. Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn’s disease but may improve pharmacokinetics. Gastroenterol Suppl 2006; 130: A-142.Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Séverine Vermeire
    • 1
  • G. Van Assche
    • 1
  • P. Rutgeerts
    • 1
  1. 1.Division of GastroenterologyUniversity HospitalsLeuvenBelgium

Personalised recommendations